Alembic Pharmaceuticals revenue up by 18% to Rs. 1486 crores in Q-1 FY24

Financial Highlights

• Net Sales grew 18% to Rs.1486 crores for the quarter.
• Net Profit for the quarter at Rs.121 crores.

Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “The company grew in all the business segments with India outperforming the market with 9% growth, Ex US generics grew 46%, API grew 31% and the US generics business grew 6%. We have also started commercializing products from our Oncology and Injectable Facilities”

Operational Highlights

India Branded Business

• Branded Business up by 9% to Rs. 524 Cr in the quarter.
• Branded Business reflected growth of 11%* better than industry growth of 9%*.
• Specialty therapies recorded growth of 12%* vis a vis industry growth of 7%*.
• Acute therapies recorded growth of 16%* vis a vis Industry growth of 10%*. In Anti Infective, Industry has shown growth of 10%* where as Alembic recorded 19%* growth.
• Animal Health business recorded growth of 11% over PY Q1.

* IQVIA Qtr June ’23 

International Business

• US Generics up 6% to Rs. 390 crores in the quarter.
• Ex-US International Formulations grew 46% to Rs. 266 Crores in the quarter.
• 5 ANDA approvals received during the quarter; 184 Cumulative ANDA approvals.
• 5 ANDA filings during the quarter; Cumulative ANDA filings at 250.

API Business

• API business grew 31% at Rs. 305 crores in the quarter.
• 131 cumulative DMF Filings.

The summary of Total Revenue is as under:   

                                                                   (Rs in Crores)